Guava Technologies is a biotechnology and medical devices company that focuses on empowering medical advancements through innovative products tailored for cell biology research and clinical diagnostics. Established in 1998, the company's product lineup includes solutions for HIV/AIDS monitoring, cell counting and viability assays, antibody quantification assays, apoptosis assays, cell cycle assays, cytotoxicity assays, and cell proliferation assays. Additionally, they provide benchtop cell analysis systems and flow cytometry systems for cell biology research, drug discovery and development, and HIV/AIDS monitoring.
Operating within the biotechnology, health care, and medical devices industries, Guava Technologies serves diverse markets, such as life science research, drug discovery, cell biology research, core flow cytometry, and clinical diagnostics. Their products find applications in areas like cell counting/viability, antibody quantification, cell cycle and proliferation, cytotoxicity, and apoptosis. After its founding, the company has operated as a subsidiary of Millipore Corp. since February 20, 2009.
The most recent investment in Guava Technologies was a $4.50M Venture Round investment on March 31, 2009. Although the specific investors for this round are not provided, this funding indicates continued support for the company's growth and development in the dynamic biotechnology and medical devices sector.
